Background: Epidermal growth factor receptor (EGFR) overexpressed in colorectal cancer (CRC) is a tumor target for developing the anti-tumor theranostic agents. Cetuximab, an anti-EGFR monoclonal antibody against EGFR-positive tumors, inhibits cell proliferation and growth was labeled with radioactive 111 indium ( 111 In) in this study for diagnosing EGFR-positive CRC. The aim of this study was to evaluate the efficacy of noninvasive nuclear imaging agent 111 In-cetuximab and investigate the biological distribution of 111 In-cetuximab in the HCT-15-induced EGFRpositive CRC tumor xenografts. Methods: We conjugated cetuximab with an isotope chelator, diethylene triamine penta acetic acid (DTPA), and consequently labeled cetuximab-DTPA with 111 In and measured the labeling efficacy by an instant thin layer chromatography (iTLC). Furthermore, the 111 Incetuximab was investigated and compared for imaging small (50 mm 3 ) and large (250 mm 3 ) tumor of CRC xenografts, respectively. Results: The conjugated ratio between cetuximab and DTPA was 1:6 measured by MALDI-TOF-MS. The better labeling concentration of cetuximab with 10 mCi of 111 In was calculated and experimented as 48 mg, resulting in labeling efficacy >80% detected by iTLC. The results revealed that the 111 In-cetuximab accumulated in the both sizes of tumors as a reliable noninvasive diagnostic agent, whereas the ratio of tumor to muscle in the large tumor was 7.5-fold. The biodistribution data indicated that the 111 In-cetuximab bound to tumor specifically that was higher than that in other organs. Conclusion: We suggested that the 111 In-cetuximab was potential for early diagnosis and prognostic monitor of EGFR-positive CRC in further clinical practice.
Introduction
Colorectal cancer (CRC) such as adenocarcinoma occurred with high incidence worldwide belonging to a malignant tumor, which is diagnosed without major symptom at an early stage. Almost 60% of CRC occurs in the developed countries. 1 Since early diagnosis of CRC improves the outcome of Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.therapeutic treatment for CRC, 2 it is urgent to develop a reliable and early CRC diagnostic agent. Moreover, CRC is always diagnosed occurring in late stage with metastasis, but the current diagnosing standard, colonoscopy with the histopathologic examination, is insufficient to detect the early tumor and metastasis.
Epidermal growth factor receptor (EGFR) overexpresses in the tissues of CRC by 97% as a cell membrane protein participating in cell proliferation. 3, 4 Literature has indicated that EGFR is a tumor target of CRC. 5e7 A previous study has developed EGFR-targeted therapeutic antibodies against CRC such as cetuximab 8 which is a chimeric monoclonal antibody. Besides, cetuximab is also utilized as a targeting probe carrying various diagnostic and therapeutic agents. 9e11 The CRC diagnosis based on the use of cetuximab is proven a promising strategy for noninvasively tracking tumor locations and monitoring the therapeutic effects.
Compared to the gold standard, colonoscopy with histopathologic examination, in diagnosing CRC, the noninvasive nuclear imaging techniques such as single-photon emission computerized tomography/computer tomography (SPECT/ CT) or positron emission tomography/computer tomography (PET/CT) provide higher sensitive diagnostic resolution and wide-screen for whole tissues in body specimen, 12e14 suggesting that early tumor diagnosis and metastasis diagnosis by nuclear imaging techniques are feasible. Based on the concept of nuclear imaging methodology, this study aimed to evaluate the noninvasive nuclear imaging technique for diagnosing EGFR-positive CRC using a radioactive isotope-chelatedcetuximab, which may provide an evidence for the consequent utilization of EGFR-specific anti-tumor therapy.
In this study, we intended to label cetuximab with 111 indium ( 111 In) (half-life ¼ 2.83 days, r-ray ¼ 0.2454 MeV) through diethylene triamine penta acetic acid (DTPA) chelator. The optimal labeling ratio was calculated and experimentally investigated. The cell binding of cetuximab-DTPA to EGFRpositive HCT-15 cells was investigated. The reliability of nuclear imaging diagnosis using 111 In -cetuximab was demonstrated in the HCT-15-induced tumor xenografts which carrying small (50 mm 3 ) and large (250 mm 3 ) tumors individually. Furthermore, the biodistribution of 111 In-Cetuximab in tumor xenografts was also investigated.
Methods

HCT-15 culture and tumor xenograft model
Human colorectal carcinoma cells (HCT-15) were purchased from the American Type Culture Collection (ATCC) and cultured in F12K medium with 10% of fetal bovine serum. HCT15 is an EGFR-positive colorectal cancer cell line with KRAS mutation 15 which model is similar to a previous study utilizing HCT116 for EGFR-nuclear imaging. 10 All cells were incubated at 37 C and 5% CO 2 . Male nude mice were purchased from BioLASCO Taiwan Co., Ltd, Taiwan. The 5-week-old mice were housed in a 12 h-light cycle at 22 C. The animal studies were approved by the institutive ethical review committee in Institute of Nuclear Energy Research, Taiwan, which followed the NIH guidelines on the care and welfare of laboratory animals. HCT-15 cells (2 Â 10 6 ) were subcutaneously (s.c.) inoculated into the right leg of nude mice. Tumors were established for 7 days as the small tumor model (50 mm 3 ) , and 30 days as the large tumor model (250 mm 3 ) before the tumor imaging.
Conjugation and measurement of cetuximab-DTPA
To create cetuximab-DTPA, cetuximab was incubated with P-SCN-Bn-DTPA (w/w 1:10, Macrocyclics, Dallas, TX, USA) in carbonate-bicarbonate buffer (pH 9.0) at room temperature for 2 h. The cetuximab-conjugated DTPA was purified using G-25 column, whereas the second ml was collected. The cetuximab and cetuximab-DTPA were added with an equal volume of sinapinic acid (20 mg/ml in 50% acetonitrile/0.5% TFA) and dried on a steel plate. The molecular weights of antibodies were analyzed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS, UltraflexIII, Bruker Daltonics GmbH, Germany).
Cetuximab-DTPA binding assay
Each HCT-15 cells (2 Â 10 6 cells) were treated with 1 mg/ ml of cetuximab-FITC for 30 min at room temperature. The 20-fold of cetuximab or cetuximab-DTPA higher than cetuximab-FITC was added simultaneously for investigating the competing capacity. After the reaction, the medium was removed and washed using phosphate-buffered saline (PBS) for three times. The cells in PBS buffer were analyzed using FACSCalibur Flow Cytometer (BD Bioscience, USA).
The labeling of 111 In-cetuximab in vitro
First, the cetuximab-DTPA was mixed and incubated with 111 In by 1:1 molar ratio. The specific radioactivity (SRA) of 111 In was calculated as following formula: 111 In, respectively, for 30 min and 24 h in PBS buffer, pH7.4. This experiment was performed just once for reason of as low as reasonably achievable (ALARA), however, the labeling rate was measured every time when applying in animal nuclear imaging. The labeling rate >80% was acceptable as performed in the tumor xenografts. The labeling efficiency was measured using instant thin layer chromatography (iTLC) on the silica gel impregnated glass fiber sheets (PALL corporation, USA), whereas PBS was used as the mobile phase. Then, the sheets were measured using a radioactive scanner (AR-2000radio-TLC Imaging Scanner, Bioscan, France).
Nuclear imaging and biodistribution in HCT-15-induced tumor xenografts
The HCT-15-induced tumor xenografts were intravenously injected with 111 In -cetuximab (n ¼ 3) or
111
In alone (n ¼ 3) by 1 mCi of radioactivity for each mouse. A Nano-SPECT/CT (Mediso Medical Imaging Systems, USA) was utilized to detect and image the tumors in the tumor model in vivo. For investigating the biodistribution of 111 In-cetuximab in EGFRpositive HCT-15-induced xenografts, the organs were harvested and measured the radioactivity using a gamma counter (1470 WIZARD, PerkinElmer, USA) after the agents and 111 In injection for 48 h. The percent injected dose per gram of tissue (%ID/g) was utilized to represent the radioactive intensity in each collected organ.
Statistical analysis
Statistical analysis was performed using GraphPad Prism V5.01 software (GraphPad Software, Inc., California, USA). All analysis data with more than two groups were performed by ANOVA followed by posthoc analysis with Bonferroni's test. Student's t-test was used to compare two groups. The significance difference was acceptable as p < 0.05.
Results
Cetuximab specifically bound to EGFRoverexpressed HCT-15 cells
To investigate EGFR expression in colorectal HCT-15 cancer cells, cetuximab was labeled with fluorescent FITC, and then the agent was purified using a G-25 column. HCT-15 cells were treated and incubated with none, 1 mg/ml of cetuximab-FITC, or 1 mg/ml of cetuximab-FITC plus 10 mg/ml of cetuximab, respectively, for 30 min at room temperature. We figured out that the fluorescent intensity in the cetuximab-FITC group was higher than that in other groups (Fig. 1A and  B) , revealing that cetuximab specifically bound to HCT-15 cells which overexpressed EGFR. 15 
Cetuximab-DTPA bound to HCT-15 cells
Cetuximab was labeled with 111 In through DTPA chelator, therefore, we first conjugated cetuximab with DTPA. We added excess DTPA to cetuximab by 10-fold for maximally conjugating DTPA to available amide groups of cetuximab. MALDI-TOF MS results showed that the molecular weight 152,153Da of cetuximab shifted as 156,176Da ( Fig. 2A) , indicating that the conjugated ratio was approximately 1:6 between cetuximab and DTPA. In order to investigate the binding capacity of cetuximab-DTPA to HCT-15 cells, 10 mg/ ml of cetuximab-DTPA was added with 1 mg/ml of cetuximab-FITC as a competitor. We found that cetuximab-DTPA reduced the binding capacity of cetuximab-FITC to HCT-15 cells (Fig. 2B and C) , revealing that cetuximab-DTPA still had the binding capacity to EGFR on HCT-15 cells.
3.3. The optimal labeling ratio of cetuximab-DTPA with 111 In
The theoretical labeling concentration of cetuximab-DTPA with 111 In is 5.73 mg of cetuximab-DTPA to 10 mCi of 111 In described in Methods and Materials. We intended to evaluate the accurate labeling ratio experimentally, 3, 6, 12, 24, 48, 96, 192, 384 , 768 mg of cetuximab-DTPA were incubated with 10 mCi of 111 In, respectively. We found that the amount of cetuximab-DTPA over 48 mg resulted in >80% labeling efficiency ( Fig. 3A and B) , indicating that the optimal labeling concentration was 48 mg of cetuximab-DTPA to 10 mCi of 111 In corresponding to the theoretical calculation. The labeling efficiency of 111 In-cetuximab was measured >80% in 24 h (Fig. 3A) , revealing that 111
In -cetuximab was stable.
111
In-cetuximab nuclear imaging and biodistribution
Since
111 In-cetuximab was created, we applied 111 Incetuximab to detect the EGFR-positive tumors in the HCT-15-induced xenografts. The 111 In-cetuximab was injected in the tumor models implanted with a small tumor (50 mm 3 ) and large tumor (250 mm 3 ) and consequently imaged using a Nano-SPECT/CT device. We found that 111 In-cetuximab accumulated in the mouse liver and tumor in 24 h poster injection, including small and large tumors ( Fig. 4A and B) . Otherwise, 111 In accumulated in kidney majorly. The radioactivity of 111 In-cetuximab in the tumor was higher in small or large tumor model compared to control group. Next, the biodistribution of 111 In-cetuximab was investigated compared to that of 111 In. The results were consistent with the SPECT/CT images showing the higher radioactivity in tumors compared to other organs in the 111 In-cetuximab-injected large tumor xenografts (Fig. 5B) . Otherwise, 111 In majorly distributed in the kidney (Fig. 5A) . The tumor to muscle ratio of 111 In -cetuximab was measured 7.5-foldwhich was higher than that of 111 In group measured as 3.1-fold (Fig. 5C ), indicating that 111 In-cetuximab specifically bound to EGFR-positive tumors as a reliable diagnosing agent. Meanwhile, the sum of radioactivity in 111 In group was higher than that in the 111 Incetuximab group (Fig. 5D) . The result indicated that 111 In labeled with cetuximab through chelator DTPA was easily excreted out the mice better than free 111 In, suggesting that this labeling method may not lead to accumulation of 111 In metal in mice.
Discussion
EGFR overexpresses in a variety of cancers, including CRC, 3, 16 head and neck cancer, 17 lung cancer. 18, 19 Therefore, diagnosing the EGFR-positive tumor is an important issue for The higher binding capacity was found in cetuximab-FITC (1 mg/ml) group measured using a flow cytometry technique, which was blocked when the 10-fold of cetuximab was added. ***p < 0.001. selecting the adequate therapy. In this study, we intended to label cetuximab with radioactive 111 In and to optimize the labeling condition for creating 111 In-cetuximab serving as a diagnostic imaging tool for CRC. Our results demonstrated that 111 In-cetuximab specifically targeted to EGFR-positive HCT-15-induced tumors, and the optimal labeling concentration was 48 mg of cetuximab with 10 mCi of 111 In. This research provided the manufactured condition for EGFR nuclear imaging agent, 111 In-cetuximab. Targeting to EGFR based on its specific antibody is useful and potential for developing the diagnostic methodology for EGFR-positive tumors. Since utilization of radiolabeled cetuximab has been applied for diagnosing tumors such as CRC 20 or head and neck tumor, 21 to investigate and optimize the labeling ratio between cetuximab and isotope was needed. Although the labeling efficiency was limited around 80% when using 48 mg of cetuximab incubated with 10 mCi of 111 In, the EGFR-positive tumor was clearly imaged and diagnosed. The higher amount of cetuximab with 10 mCi of 111 In led to increased labeling efficiency, however, the unlabeled cetuximab played as a competitor blocking the binding of 111 In-cetuximab similar to a study published by Nayak et al. using co-injection of cetuximab with 86 Y-labeled cetuximab. 22 Therefore, finding the optimal radio-labeled rate is necessary for improving the radio-imaging signals. Previously, Shih et al. have utilized 100 mg of cetuximab to label with 10 mCi of 111 In, resulting in similar radio-labeled rate (~80%). 10 Although the radio-labeled rate >80% is acceptable for a nuclear imaging application, the extra unlabeled cetuximab may reduce the radioactive signals in real practice, leading to lower resolution of nuclear imaging. According to their data, they have declared that 111 In-cetuximab leads to highest In, respectively. The labeling efficiency was determined using iTLC. The higher amount of cetuximab-DTPA increased the labeling efficiency, but the limit was around 80% shown by the arrow whereas 48 mg of cetuximab-DTPA was incubated with 10 mCi of radioactive signals in 72 h after injection by tail vein. However, we not only detected the HCT-15-derived large tumors in 24 h but also detected the small tumors, implying the optimal labeling ratio was significant for nuclear imaging. Therefore, in order to obtain a better and higher radioactive imaging, we suggested that the labeling ratio: 48 mg of cetuximab with 10 mCi of 111 In was adequate. Currently, cetuximab has been labeled with 111 In, No matter what radioactive isotopes are selected to label with cetuximab, the optimal labeling ratio is equivalent to the result demonstrated in this study.
111
In-cetuximab was demonstrated to diagnose an early small tumor and advanced large tumor in this study. Due to the labeling of isotope was through DTPA chelator, further radiotherapy using b À -emitted yttrium-90 ( 90 Y through DTPA) chelating is feasible.
30e32 90 Y-cetuximab combined with external irradiations had been demonstrated to reduce tumor size in a 3D cell assay. 33 Moreover, 111 In-cetuximab may be used to diagnose the prognosis of chemotherapy, tumor metastasis, and the cetuximab-derived resistance. This study addressed and evaluated the correct labeling ratio, nuclear imaging, and biodistribution of 111 In-cetuximab. Beside tumors, 111 In-cetuximab was also highly accumulated in the liver which also overexpresses EGFR. 34 The biodistribution results indicated the equal radioactive intensity between tumor and liver in a large tumor model in 48 h. Since In-cetuximab rapidly excreted from the tumor xenograft mice. *p < 0.05. **p < 0.01. existed location of the colon is distinguished from the liver, the nuclear imaging of CRC using 111 In-cetuximab may be not interfered by that from the liver. However, the acute toxicity in the liver is needed to be monitored in the performance of 111 In-cetuximab, particularly in the patients with liver diseases. Moreover, for detecting the tumor metastasis in the liver, this nuclear imaging technique based on 111 In-cetuximab is inadequate. Other techniques are needed for assisting the diagnosis of tumor metastasis in liver.
In conclusion, we evaluated that 111 In-cetuximab was useful for detecting an EGFR-positive tumor, and optimized the labeling ratio between cetuximab and radioactive 111 In. The theoretically labeling ratio was equivalent to the experimental result, which may be applied in another labeling pair of antibody and isotope. We suggest that optimal labeling of 111 In-cetuximab can be used to diagnose EGFR-positive CRC.
